Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

Gulf War Illness Nasal Irrigation Study

NCT01700725
Conditions
Persian Gulf Syndrome, Chronic Sinusitis, Fatigue, Acute Sinusitis
Interventions
Nasal Irrigation - Saline, Nasal Irrigation - Xylitol
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Fatigue Syndrome, Chronic
Interventions
Naltrexone HCl
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Chronic Fatigue Syndrome, Chronic Fatigue, Fibromyalgia
Interventions
Amygdala Retraining Program
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 59 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Medically Unexplained Chronic Fatigue, Chronic Fatigue Syndrome
Interventions
Cognitive-behavioral self-management, Symptom monitoring
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Chronic Fatigue Syndrome
Interventions
valganciclovir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Stanford, California
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

NCT01071044
Conditions
Chronic Fatigue Syndrome, Cognitive Impairments
Interventions
Lisdexamfetamine Dimesylate, Placebo "30, 50 or 70 mg"
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester Hills, Michigan
Conditions
Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia, Dysgeusia, Brain Fog, Muscle Pain, Shortness of Breath, Dizziness, Fatigue Post Viral, Cough, Menstrual Cycle Abnormal, Pain
Interventions
Stellate Ganglion Block
Procedure
Lead sponsor
Metamorphosis LTD
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cañon City, Colorado
Conditions
Lyme Disease
Interventions
Transcranial Direct Current Stimulator
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Cancer Survivor, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Depression, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Psychosocial Effects of Cancer and Its Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
internet-based intervention, questionnaire administration, psychosocial assessment and care, assessment of therapy complications, management of therapy complications, fatigue assessment and management, counseling intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years and older
Enrollment
1,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
Interventions
Computed Tomography of the Chest
Diagnostic Test
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myalgic Encephalomyelitis, Long-COVID
Interventions
Rapamycin
Drug
Lead sponsor
Simmaron Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Rochester, Minnesota • Incline Village, Nevada + 2 more
Conditions
Chronic Fatigue Syndrome
Interventions
Sildenafil (Viagra), Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome
Interventions
Amantadine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19, Cancer in Remission With Persisting Fatigue
Interventions
Immediate Autoimmune Intervention Mastery Course (AIM), Immediate Question and Answer sessions. (AIM Q and A sessions), Delayed Autoimmune Intervention Mastery Course (delayed AIM course), Delayed AIM Question and Answer sessions
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
ME/CFS, IBS - Irritable Bowel Syndrome
Interventions
Floradapt Intensive GI, Placebo
Drug · Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Temporarily Not Available No phase listed Expanded access Accepts healthy volunteers

Ampligen in Chronic Fatigue Syndrome

NCT00215813
Conditions
Chronic Fatigue Syndrome
Interventions
Poly I: Poly C12U (Rintatolimod)
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Incline Village, Nevada • Charlotte, North Carolina
Terminated No phase listed Observational Accepts healthy volunteers

Whole Body Hyperthermia Registry Study

NCT02174003
Conditions
Depression, Anxiety, PTSD, Fibromyalgia, Chronic Fatigue Syndrome
Interventions
High intensity whole-body infrared heating
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Covid19, ME/CFS, SARS COV2, Novel Coronavirus Infection, Neurocognitive Disorders, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Timeline
2020 – 2025
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Completed Not applicable Interventional

Fatigability in Long COVID-19

NCT05699538
Conditions
Long COVID
Interventions
Minimal-Dose Home-Based Resistance Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Not listed No phase listed Observational Accepts healthy volunteers

Use of a Monitor in ME/CFS

NCT01908036
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
New York CFS Association
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional

Hydrogen Water Dosing Study for ME/CFS

NCT06227273
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions
Hydrogen water
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stony Brook, New York